Swedish govt investing 80 million kronor in genomic medicine
The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic Medicine Sweden (GMS) in 2025.
The money will be used, among other things, for a national implementation project of whole genome sequencing for rare health conditions, the implementation of precision-based diagnostics in cancer and infectious diseases, which includes the identification of antibiotic resistance. All initiatives will also ensure the equal introduction of precision health in healthcare.
The initiative promotes the implementation of precision medicine, which pharma trade group the Lif sees as a welcome priority. The government's support for GMS is a clear signal that it is an important area for Sweden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze